In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Additionally, the company will need to navigate the competitive landscape in areas like generalized myasthenia gravis (gMG), where nipocalimab will face entrenched players. Looking ahead, Johnson & ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

And at the tail end of 2020, a $6.5 billion deal to buy Momenta meant that J&J added potential inflammatory disease blockbuster nipocalimab to the pipeline at Janssen.

Myasthenia gravis is an antibody-mediated disease of the motor endplate that leads to impaired neuromuscular transmission. 1 Pathogenic antibodies directed against antigens such as the postsynaptic ...

The author has completed the ICMJE form and declares the following conflicts of interest: She is a research assistant and principal investigator at a fetal medicine centre involved in the nipocalimab ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response rate of 61% compared to 40% for investigator’s choice of chemotherapy. Pfizer ...